Two new broker notes out last week on this one -

Collins Stewart gives a target valuation for the combined entity of 26 million or 156p per share

Edison Investments embedded valuation is 31m - Indicating a 100% gain in share price from current levels. They suggest that using the current embedded valuation model, the current value of Angles six non-exited ventures is only 5.5m - suggesting Angle to be SIGNIFICANTLY UNDERVALUED

Have a look

Very promising!

Superb.

LISTEN: Angle Plc (AGL) - Interim results

Click here to listen

Interim Results

Highlights in the year to date

· Balance sheet and specialist medtech focus strengthened by sale of Geomerics in December 2013 to ARM Holdings plc for up to £6.2 million in cash with £5.5 million already received

· Product development completed for the Parsortix system for both research and clinical use

· CE Mark authorisation secured for the Parsortix cell separation system for use as an in vitro diagnostic device in the European Union in the treatment of patients

· University of Surrey Oncology Group completed its validation of Parsortix technology, using colorectal cancer cells. The Parsortix system demonstrated twice the sensitivity of currently accepted clinical practice for CTC capture

· Cancer Research UK's Paterson Institute for Cancer Research identified key clinical advantages for the Parsortix system and has included Parsortix in its ongoing efforts to deliver personalised medicine

· Specialist, larger scale manufacturer appointed to manufacture the Parsortix system with the necessary quality systems and capacity to support roll out into the market

· Partnership with the Medical Research Council's Cancer Unit at the University of Cambridge to establish a Cambridge Parsortix Laboratory

· Appointment as a Scientific Adviser of Dr Harold Swerdlow, a world-leading expert in next generation sequencing (NGS) and Head of R&D at the Wellcome Trust Sanger Institute

· Loss for the half year of £0.5 million (H1 2013: loss £0.4 million)

· Cash balance at 31 October 2013 of £0.4 million (30 April 2013: £1.8 million). Cash position subsequently strengthened with the sale of Geomerics

Down today...but this is a very promising company with huge potential if Parsortix gets adopted worldwide !....

Parsortix Launch at Circulate Conference in Berlin

ANGLE plc (AIM: AGL), the specialist medtech company, is pleased to announce that it is launching its Parsortix non-invasive cancer diagnostics system at the 4th Annual Circulate conference in Berlin on 19 and 20 February 2014.

Circulate is an annual conference for scientists, medical researchers, diagnostic and pharmaceutical companies pioneering the emerging field of circulating tumour cells (CTCs) and circulating cancer biomarkers.

At the conference, Mr Hari Nageswaran, a Clinical Research Fellow from the University of Surrey, will present initial data from a study entitled 'Use of a new size based CTC capture and harvest technology for colorectal cancer studies'. Mr Nageswaran used ANGLE's Parsortix system to carry out the study.

ANGLE's Parsortix system enables the capture of CTCs from cancer patient blood for mutational analysis. The Parsortix system uses a simple blood test to capture the cancer cells for analysis in contrast to the established solid tumour biopsy process where cells are surgically removed from the primary tumour. The Company's liquid biopsy has key medical advantages in that (i) being a simple blood test, it is non-invasive (ii) it can be used for inaccessible tumours where a solid biopsy is not possible or is very difficult and (iii) it can be repeated as often as required during the patient's treatment, which is important as the patient's cancer mutates over time.

Following ANGLE's successful deployment of the Parsortix system with key opinion leaders, and the Company's success in securing a CE Mark for the product, ANGLE is now making the Parsortix system available for sale to the European clinical market.

ANGLE's Founder and Chief Executive, Andrew Newland, commented:
"We believe that the ability of our patented Parsortix system to capture CTCs from patient blood opens a wide range of potential applications in treating cancer patients and we look forward to attending the Circulate conference and discussing that capability with key industry, medical and research players involved in personalised cancer care. We also look forward to Mr Nageswaran's presentation and his insight into the medical significance of the Parsortix system."

Just repeating myself, but 200p plus could be on the cards...(with sales and contracts)...

Use of Parsortix System with Liver Cancer Patients

USE OF PARSORTIX SYSTEM WITH METASTATIC LIVER CANCER PATIENTS
AND UPDATE FOLLOWING CIRCULATE CONFERENCE

ANGLE plc (AIM: AGL), the specialist medtech company, is pleased to announce initial findings from a study using ANGLE's Parsortix system to analyse circulating tumour cells (CTCs) in metastatic liver cancer patients.

Mr Hari Nageswaran, a Clinical Research Fellow from the University of Surrey's Oncology Department, presented initial data from the study at the 4th Annual Circulate conference in Berlin. Circulate is an annual conference for scientists, medical researchers, diagnostic and pharmaceutical companies pioneering the emerging field of CTCs and circulating cancer biomarkers.

In the study, entitled 'Use of a new size based CTC capture and harvest technology for colorectal cancer studies', the Parsortix system was used to investigate the number of CTCs in the blood of colorectal cancer patients who, following surgery to remove the cancer from the colon and chemotherapy, had relapsed with secondary liver cancer. The study compares the CTC count in the peripheral and hepatic (liver) veins, from bloods taken during surgery to remove a section of the liver.

Even though these patients had undergone surgery to remove their primary tumour and had chemotherapy, the Parsortix system was still able to capture CTCs, from 2ml blood samples, in the peripheral blood of 65% of the patients and in the hepatic blood of 82% of the patients, a significantly higher proportion than might be expected with other systems.

The study revealed a higher concentration of CTCs found in the hepatic blood than the peripheral blood, indicating that CTC concentration in the blood is higher when in closer proximity to the location of the secondary cancer.

The study has now been extended to investigate the CTC concentration in the hepatic vein before and after surgery and the initial findings suggest that the concentration of CTCs is higher after surgery than before.

If further work confirms that this is the case, then it will be an important finding as it will indicate that the process of surgery itself may result in the release of CTCs into the bloodstream.

Further information on Mr Nageswaran's findings is available on ANGLE's website at: www.angleplc.com/partnering.asp

4th Annual Circulate conference

ANGLE showcased its Parsortix system at the Circulate conference. The Parsortix system is now available for sale for CTC research and, within Europe, for clinical use in patient care.

There was considerable interest in the Parsortix system from conference participants, primarily experts in the field of CTCs with a good understanding of emerging medical science in the field.

The Parsortix system was well received and the core competitive advantages of the system were recognised.


ANGLE's Founder and Chief Executive, Andrew Newland, commented:
"We are delighted that use of the Parsortix system by Mr Nageswaran as part of his clinical research may, if the initial data points are confirmed, lead to important medical findings for the benefit of liver cancer patients in the future.

"We are also pleased with the interest in the Parsortix system seen at the Circulate conference and enthusiastic about the potential for the adoption of the system as part of a new approach of personalised care in treating cancer patients over the coming years."

Blue today.....good progress here...

Appointment of Scientific Adviser

Looking good.....200p plus is my target....42 million market cap.....imagine if hospitals all over the world adopt their cancer cell trap system....

Intellectual Property Update

Yep...progressing nicely.....

RF - do you still follow these - the up trend is well and truly broken.

Yes...not too happy....expected a better performance from the sp...will stay put...perhaps some good news is on the way...

They are on my wish list - it looks like things may become clearer later this year.

Parsortix Evaluation

Upward trend here....nice....

Learn from the experts



You can now book your free tickets for our big event on Saturday 13 September in partnership with the London Stock Exchange. Held at the Business Design Centre in Islington, North London, The Stock Market Show is a full day event designed to help you understand investing. We have secured a large number of financial experts to explain in simple terms how you should go about investing in the stock market, the ways in which to research individual stocks and how to use different investment and trading accounts.



Tickets for the event are free but must be booked in advance you can also book your seminar sessions on our five separate stages.

The day is about to become a hot talking point among investors across the country as we are very pleased to announce This is Money as our media partner, a website read by millions of people and part of the Daily Mail & General Trust (DMGT) media stable.

• Hear from more than 50 speakers across 5 stages including: product experts, CEOs from listed companies and renowned journalists from Shares including Daniel Coatsworth, Mark Dunne, Steven Frazer and Tom Sieber who will all be giving presentations on investing.

• Speak with over 40 exhibitors from a range of AIM companies brokers and platform providers including: Alecto Minerals, Advanced Computer Software Group, Angle, Avation, Azonto Petroleum, Chaarat Gold, Corero Group Services, eg Solutions, EMIS, Fastnet Oil & Gas, Flowgroup, Fox Marble, Getech, Horizon Discovery, InternetQ, NetDimensions, Nostra Terra Oil & Gas, Premier African Minerals, Valirx, Velocys, Wishbone Gold and XL Media.

• Learn about investment topics tailored to suit a range of investors from novice to expert

• Meet with top financial services providers including; Aberdeen Asset Management, AJ Bell Youinvest, Amati Global Investors, Boost, CMC Markets, ETF Securities, Hargreaves Lansdown, IG, Killik & Co, KPMG, London Stock Exchange, Panmure Gordon, Reyker Securities,Société Générale, Stockopedia and ThisisMoney.


Why you should attend:

We have structured the entire programme around one core principal: financial education



Learn about:

• What you need to become a successful investor

• Managing your own pension using stocks and shares

• The simple approach to valuing companies

• The importance of risk when researching stocks

• The most important areas in company documents and financial accounts

• Reading chart patterns

• An introduction to exchange traded funds and bonds

• Plus a host of other topics on industry sectors, trading techniques, market mechanics and tax issues



Hear from:

• Shares journalists

• Financial services professionals

• Chief executives of quoted companies

• Leading market commentators



Your chance to meet:

• Share dealing and pension providers

• Quoted companies

• Shares journalists

• Representatives from the London Stock Exchange

• Fellow investors

For more information and to register go to: http://www.thestockmarketshow.com/

Could rocket if this becomes some sort of universal standard for cancer cell capture worldwide !.......profits could be staggering !....